

Study 147

Ozcan L, Polat EC, Kocaaslan R, Onen E, Otunctemur A, Ozbek E. Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. *Andrologia*. 2017;49(9):10.1111/and.12751. doi:10.1111/and.12751

Funding: Internal Funding.

Amendments: None.

Study 148

Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A. Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. *J Sex Med*. 2006;3(4):716-722. doi:10.1111/j.1743-6109.2006.00264.x

Funding: Industry ties – Eli Lilly – Italia

Amendments: None.

Study 149

Goldfischer ER, Kim ED, Seftel AD, Baygani SK, Burns PR. Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. *Urology*. 2014;83(6):1326-1333. doi:10.1016/j.urology.2014.02.019

Funding: Industry Funded & Conflicts of Interest (researchers are salaried by Industry) – Eli Lilly

Amendments: None.

Study 150

Narukawa T, Soh J, Kanemitsu N, Harikai S, Fujihara A, Ukimura O. Efficacy of testosterone replacement therapy plus alternate-day tadalafil for patients with late-onset hypogonadism: An open-label, randomized, crossover study. *Int J Urol*. 2021;28(4):376-381. doi:10.1111/iju.14468

Funding: Industry Ties – Nippon Shinyaku

Amendments: None.

Study 151

Aversa A, Fittipaldi S, Francomano D, et al. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization. *Endocrine*. 2017;56(3):639-648. doi:10.1007/s12020-016-1208-y

Funding: Public Funding.

Amendments: None.

Study 152

Mulhall JP, Brock GB, Glina S, Baygani S, Donatucci CF, Maggi M. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking

Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials. *J Sex Med.* 2016;13(5):843-851. doi:10.1016/j.jsxm.2016.02.163

Funding: Industry Funding, Conflicts of Interest (Researchers salaried by Industry) – Eli Lilly

Amendments: None.

Study 153

Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). *J Sex Med.* 2011;8(1):284-293. doi:10.1111/j.1743-6109.2010.01956.x

Funding: Industry Funded – Bayer-Schering Pharma.

Amendments: None.

Study 154

Park NC, Kim TN, Park HJ. Treatment Strategy for Non-Responders to PDE5 Inhibitors. *World J Mens Health.* 2013;31(1):31-35. doi:10.5534/wjmh.2013.31.1.31

Funding: Public.

Amendments: None.